Market Newsdesk

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) — TransPerfect, the world’s largest provider of language and technology solutions for global business, today announced the launch of GlobalLink OneLink^® JS, an extension of the award-winning GlobalLink OneLink website localization platform, which currently powers over 5,000 multilingual websites for leading brands across the globe.

GlobalLink
OneLink automates the process of translating and releasing websites. With nothing to install, OneLink virtually eliminates IT involvement and requires no client-side project management. Organizations can launch new multilingual websites in as few as 30 days and maintain them in sync with their source thanks to fully automated change detection. 

Built on a new JavaScript-based architecture, OneLink JS is the next generation of the OneLink product family. As an alternative to the HTTP proxy approach, OneLink JS functions without the complex engineering typically associated with localization of sites authored in JavaScript. 

With OneLink JS, users can:

• Localize websites built with HTML or JavaScript frameworks, including React, Angular, and Vue.js
• Reduce overall costs and turnaround times to launch digital content into multiple languages
• Track up-to-date global usage of translated websites with JavaScript-generated tracking metrics
• Edit translations in real time with our WYSIWYG in-context review
• Translate content behind the firewall or in QA/testing areas without IT involvement
• Integrate with neural AI or MT engines.

Joe Kuefler, Division President for TransPerfect’s GlobalLink OneLink group, remarked, “The proxy technology in the first version of OneLink made localizing websites simple, but now OneLink JS makes it essentially effortless. Two lines of JavaScript code and you’ve done all the technical work you need to launch a website into a new language.”

Phil Shawe, President and CEO at TransPerfect, stated, “OneLink JS is a major leap forward for website localization technology. Translating websites based on JavaScript has never been easier. I’m proud of our development teams and their relentless drive for innovation.”

For more information, visit https://globallink.translations.com/products/onelink/.

About TransPerfect

TransPerfect is the world’s largest provider of language services and technology solutions for global business. From offices in over 100 cities on six continents, TransPerfect offers a full range of services in 170+ languages to clients worldwide. More than 5,000 global organizations employ TransPerfect’s GlobalLink® Product Suite to simplify management of multilingual content. With an unparalleled commitment to quality and client service, TransPerfect is fully ISO 9001 and ISO 17100 certified. TransPerfect has global headquarters in New York, with regional headquarters in London and Hong Kong. For more information, please visit our website at www.transperfect.com.

Contact
:

Ryan
Simper
+1 212.689.5555


[email protected]

ATLANTA and SYDNEY, Australia, Nov. 16, 2020 (GLOBE NEWSWIRE) — Today, First Advantage, a global leader in background check solutions, announced that it received a Gold HR Service Provider Award from Human Resources Director (HRD) magazine for pre-employment screening. This is the company’s second consecutive win.

HRD shared, “Finding a dependable service provider can be quite the daunting task for HR professionals. From an impressive array of vendors offering their expertise, HR professionals need to choose the one that suits their company’s unique needs. By outsourcing some of the day-to-day office requirements to a trusted partner, the HR team can focus on the company’s long-term business strategy and goals.”

As such, the annual awards program aims to assist HR professionals with this task by recognizing HR service providers across eight categories, including screening and assessment. A panel of judges reviewed all entrants, with the top three submissions in each category receiving gold, silver and bronze HRD HR Service Provider Awards, respectively.

With regard to First Advantage, HRD commented, “It has the ability to provide effortless, global background check services with the right technology – from criminal record searches; education, employment, and professional license verifications; global sanction searches; credit checks; to medical screening; and more. And unlike other background screening organizations that purport to be global, First Advantage has a truly global infrastructure.”

James T. Heeney, vice president, Head of Australia and New Zealand for First Advantage, said, “While 2020 presented its challenges, First Advantage remained steadfast in our role as a global technology partner, providing our customers with solutions and services designed to meet today’s business conditions. It’s an honor to receive the Gold HR Service Provider Award for the second year in a row, as we continue to navigate these unique times.”

To read more, visit https://www.hcamag.com/au/news/special-reports/hr-service-provider-awards-2020/first-advantage/238547.

A
bout First Advantage

First Advantage provides comprehensive background screening, identity and information solutions that give employers access to actionable information that results in faster, more accurate people decisions. With an advanced global technology platform and superior customer service delivered by experts who understand local markets, First Advantage helps customers around the world build fully scalable, configurable screening programs that meet their unique needs. Headquartered in Atlanta, Georgia, First Advantage has offices throughout North America, Europe, Asia and the Middle East.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/959b392f-9944-4ef8-b0ce-5e2a5a8f7d04

NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc. and its affiliate TeneoFour, Inc. announced today a Nature Metabolism publication (https://www.nature.com/articles/s42255-020-00298-z) of a proof of concept study by the Chini Laboratory (Mayo Clinic’s campus in Rochester, Minnesota) describing the rejuvenation of energy metabolism in aged mice undergoing therapy with Teneobio’s CD38 blocker.

The presented findings demonstrate that chronic inflammation (“inflammaging”) mediated by senescent cells induces a CD38-mediated decline in precursors involved in cellular health and energy metabolism. Specific inhibition of CD38 using Teneobio’s CD38 specific antibody raised levels of these precursors and restored nicotinamide nucleotide homeostasis in aged animals.

Wim van Schooten, Chief Scientific Officer at Teneobio, said, “Boosting NAD+ levels and Sirtuin activity are known for their strong anti-inflammatory and tissue protective effects. Repair of inflammation-related decline of NAD+ could be an effective therapy of aging -associated diseases such as fibrosis and metabolic disorders. Teneobio plans to initiate clinical trials with this exciting new anti-CD38 therapeutic in the first half of 2021.”

About
Teneobio
, Inc.

Teneobio, Inc. is a clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb®), for the treatments of cancer, autoimmunity, and infectious diseases. Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDab®) derived from UniAb® can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. Teneobio’s “plug-and-play” heavy chain antibody platform includes a diverse set of immunomodulatory antibodies for therapeutics with optimal efficacy and reduced toxicity.

Teneobio partners include AbbVie, Janssen, GSK, Kite and Poseida, Intellia and ArsenalBio.  For more information, please visit www.teneobio.com.

About TeneoFour, Inc.

TeneoFour, Inc. is a spinout of Teneobio, Inc. developing anti-CD38 heavy chain antibodies that block the enzyme functions of CD38. TeneoFour, Inc. owns all rights to products and intellectual property generated at Teneobio, Inc. regarding human heavy chain antibodies specific for CD38.

Company Inquiries for
Teneobio
, Inc.
and TeneoFour, Inc.

Omid Vafa, Chief Business Officer
[email protected]

ROGERSVILLE, Tenn., Nov. 16, 2020 (GLOBE NEWSWIRE) — This election year has revealed that the two-party system has contributed to stark division among Americans. With all eyes on newly elected state and federal officials, James Weart, a proud American, military veteran and criminal defense attorney with over forty years of experience, shares why now is the best time to establish a third political party into government. His new book, “Common Sense: A Real Party Movement” analyzes American history from the original thirteen colonies to the formulation of U.S. government to narrow in on how politics reached this boiling point and what changes can be made to the party system to save the country from further political divide.

Exploring the country’s historic roots, Weart shares warnings from George Washington in 1797 regarding the realities of governmental stagnation and deadlock caused by a two-party system. Knowledge of America’s fascinating history shines a light on the balance another political party could have on the middle class who, Weart notes, are not properly represented by the Republican and Democratic parties.

Weart explains how the rich and dominant elite run the two political parties as an oligarchy instead of a democracy and ignore the struggles of the middle class who elected them to power. He proposes that a new party, the Real Party of America, would better represent the average citizen and renew traditional founding values.

With a focus on curtailing government spending, resolving the COVID-19 crisis, repairing infrastructure and providing affordable health care, the Real Party of America would restore the country with elected officials that truly represent the middle class.

Providing honest findings on the country’s current political standing, “Common Sense: A Real Party Movement” drives readers to explore solutions to restore America’s moral compass and educate themselves on the importance of better representation for the future of this country.

“Common Sense: A Real Party Movement”

By James Weart, Juris Doctor

ISBN: 978-1-6632-1024-1 (softcover); 978-1-6632-1023-4 (electronic)

Available at the iUniverse Online Bookstore, Amazon and Barnes & Noble

About the author

James C. Weart was raised in a military family that moved regularly and thus saw different parts of the country. In 1970, he graduated from Stetson University with a Bachelor of Arts in History and Political Science. He was commissioned as a Second Lieutenant in the U.S. Army and assigned to the Engineer Corps. He graduated from Mercer Law School with a Juris Doctor in 1976, later becoming a successful criminal defense lawyer in Orlando, Florida for 42 years. In 2017 and 2018 he was proclaimed one of the ten best criminal lawyers in the State of Florida by several national organizations. He is retired and currently resides in the mountains of Eastern Tennessee with his wife and three dogs.

iUniverse, an Author Solutions, LLC, self-publishing imprint, is the leading book marketing, editorial services, and supported self-publishing provider. iUniverse recognizes excellence in book publishing through the Star, Rising Star and Editor’s Choice designations—self-publishing’s only such awards program. iUniverse is headquartered in Bloomington, Indiana. For more information or to publish a book, please visit iuniverse.com or call 1-800-AUTHORS.

Attachment

• 820331HighRes

Georgetown, Kentucky, Nov. 16, 2020 (GLOBE NEWSWIRE) — Ecofibre Limited (Ecofibre, Company) (ASX: EOF, ADR: EOFBY) today announced it will sponsor an American Depository Receipt (ADR) program to improve access for investors in the United States (U.S.). 

Deutsche Bank Trust Company Americas (Deutsche) has been appointed depositary bank for the program which became available for trading in the U.S. on Thursday, November 12, 2020. Ecofibre’s ADR will trade in the U.S. over-the-counter (OTC) market under the symbol EOFBY. One Ecofibre ADR represents four existing Ecofibre ordinary shares. 

The ADR program does not involve the issuance of new shares or the raising of new capital by the Company. 

ADRs allow U.S. investors to buy shares in foreign companies through U.S. registered securities without the need for cross-border or cross-currency transactions. They are priced in U.S. dollars and can be traded like shares of U.S. based companies. 

Ecofibre’s ordinary shares may also continue to trade on the OTC market in the U.S. as foreign securities under the ticker code EOFBF. 

Ecofibre will remain a member company of the Nasdaq International Designation and is not listed or traded on the NASDAQ Stock Market, LLC.  

About Ecofibre

Ecofibre is a provider of hemp products in the United States and Australia.

In the United States, the Company produces nutraceutical products for human and pet consumption, as well as topical creams and salves. See www.anandahemp.com and www.anandaprofessional.com.

In Australia, the Company produces 100% Australian grown and processed hemp food products including protein powders, de-hulled hemp seed, and hemp oil. See www.anandafood.com.

The Company is also developing innovative hemp-based products in textiles and composite materials in partnership with Thomas Jefferson University (TJU) in the United States. See www.hempblack.com.

The Company owns or controls key parts of the value chain in each business, from breeding, growing, and production to sales and marketing. Our value proposition to customers is built on strong brands and quality products. 

###

LOS ANGELES, Nov. 16, 2020 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 14, 2020 to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Turquoise Hill Resources Ltd. (“Turquoise Hill” or the “Company”) (NYSE: TRQ) securities between July 17, 2018 and July 31, 2019, inclusive (the “Class Period”).

If you suffered a loss on your Turquoise Hill investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/turquoise-hill-resources-ltd/.

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On February 26, 2019, the Company announced in a press release that, while “the [Oyu Tolgoi] project cost was expected to remain within the $5.3 billion budget,” a review had determined that “there was an increasingly likely risk of a further delay to sustainable first production beyond Q3‘21.” Turquoise Hill attributed the “likely risk” to productivity setbacks in completing Shaft 2 and “challenging ground conditions that have had a direct impact on the project’s critical path.”

On this news, the Company’s share price fell $0.27, or approximately 13%, to close at $1.83 per share on February 27, 2019, thereby injuring investors.

Then, on July 15, 2019, Turquoise Hill announced that sustainable first production from the underground development of Oyu Tolgoi would now be delayed by another 9 to 21 months until May 2022 to June 2023. The Company also stated that “the development capital spend for the project may increase by $1.2 to $1.9 billion over the $5.3 billion previously disclosed.”

On this news, the Company’s share price fell $0.47, or 44%, to close at $0.60 per share on July 16, 2019, thereby injuring investors further.

Then, on July 31, 2019, after the market closed, Turquoise Hill disclosed that it had taken a $600 million impairment charge and a significant “deferred income tax recognition adjustment” tied to the Oyu Tolgoi project, and that it had suffered a loss in the second quarter.

On this news, the Company’s share price fell $0.05, or over 8%, to close at $0.53 per share on August 1, 2019, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the production of underground development of Oyu Tolgoi was not proceeding as planned; (2) there were substantial undisclosed underground stability problems that called into question the design of the mine and the projected cost and timing of production; (3) Turquoise Hill’s publicly released estimates of the cost, date of completion, and dates for production from the underground mine were not attainable; (4) the development capital required for the underground development of Oyu Tolgoi would cost substantially more than a billion dollars over what Turquoise Hill had represented; (5) Turquoise Hill would require additional financing and/or equity to complete the project; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.   

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Turquoise Hill securities during the Class Period, you may move the Court no later than December 14, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com  
[email protected]

BENSALEM, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) — Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected].

Garrett Motion Inc. (NYSE: GTX, OTC: GTXMQ)
Class Period: October 1, 2018 – September 18, 2020
Lead Plaintiff Deadline: November 24, 2020

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that, due to its agreement to indemnify and reimburse Honeywell for certain asbestos-related liability, Garrett was saddled with an unsustainable level of debt; (2) that, as a result, Garrett had a highly leveraged capital structure that posed significant challenges to its overall strategic and financial flexibility; (3) that, as a result of the foregoing, Garrett’s ability to gain or hold market share was impaired; (4) that, as a result of the foregoing, the Company was reasonably likely to seek bankruptcy protection; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. 

BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN)
Class Period: February 28, 2020 – August 18,2020
Lead Plaintiff Deadline:  November 24, 2020

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (2) as a result, it was foreseeable that the FDA would not approve the BLA for valoctocogene roxaparvovec without further data; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Peabody Energy Corporation (NYSE: BTU)
Class Period: April 3, 2017 – October 28, 2019
Lead Plaintiff Deadline: November 27, 2020

Shareholders with $250,000 losses or more are encouraged to contact the firm

The complaint alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Peabody had failed to implement adequate safety controls at the North Goonyella mine to prevent the risk of a spontaneous combustion event; (2) Peabody failed to follow its own safety procedures; (3) as a result, the North Goonyella mine was at a heightened risk of shutdown; (4) Peabody’s low-cost plan to restart operations at the North Goonyella mine posed unreasonable safety and environmental risks; (5) the Queensland Mines Inspectorate (“QMI”), the Australian body responsible for ensuring acceptable health and safety standards, would likely mandate a safer, cost-prohibitive approach; (6) as a result, there would be major delays in reopening the North Goonyella mine and restarting coal production; and (7) that, as a result, of the foregoing, Defendants’ statements about the Peabody’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Pintec Technology Holdings Limited (NASDAQ: PT)
IPO: October 2018
Lead Plaintiff Deadline: November 30, 2020

The complaint alleges that the Registration Statement was false and misleading and omitted to state material facts. Specifically, Defendants failed to disclose to investors: (1) that Pintec erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) that there were material weaknesses in the Company’s internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) that, as a result of the foregoing, Pintec’s financial results for fiscal 2017 and 2018 had been misstated; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Pintec’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com